[Form 4] Protalix BioTherapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Protalix BioTherapeutics director Aharon Schwartz purchased 129,000 shares of Protalix (PLX) common stock on 06/10/2025 at a weighted average price of $1.596 per share, with execution prices ranging from $1.575 to $1.60 across multiple trades. Following the reported purchase, the reporting person beneficially owned 303,000 shares.

The filing identifies Mr. Schwartz as a director and shows the transaction coded as a purchase. The report notes the transaction was executed in multiple trades and that the reporting person will provide full trade-by-trade details upon request to the SEC staff, the issuer, or a security holder.

Positive

• Director purchase disclosed: Aharon Schwartz acquired 129,000 shares of PLX common stock.
• Clear pricing and execution transparency: Weighted average price reported as $1.596, with execution range $1.575–$1.60 and an undertaking to provide trade-level details upon request.
• Updated beneficial ownership: Reporting person now beneficially owns 303,000 shares.

Negative

• None.

Insights

Financial Analyst

Insider purchase increased a director's stake to 303,000 shares; transaction size and price are clearly disclosed.

The disclosure shows a director acquired 129,000 shares at a weighted average of $1.596 per share, executed across multiple trades between $1.575 and $1.60. The report provides concrete share counts before and after the trade and includes an offer to provide trade-level details on request. Without outstanding share count or market-cap context in this filing, the absolute transaction size cannot be judged material, so the immediate market-impact assessment is limited to the clear factual change in beneficial ownership.

Corporate Governance Expert

Director filing is a routine Section 16 disclosure showing a purchase and updated beneficial ownership.

The Form 4 identifies the reporting person as a director and records a purchase (code P) that raises beneficial ownership to 303,000 shares. The explanatory note documents multiple trades and provides a weighted average price, which supports transparency and compliance with Section 16 reporting requirements. The filing does not indicate any amendment, plan-based transaction, or change in relationship status beyond the director designation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schwartz Aharon

(Last) (First) (Middle)

C/O PROTALIX BIOTHERAPEUTICS, INC.

2 SNUNIT STREET SCIENCE PARK, POB 455

(Street)

CARMIEL L3 2161401

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Protalix BioTherapeutics, Inc. [ PLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2025		P		129,000	A	$1.596(1)	303,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $1.60 to $1.575 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

	/s/ Joseph R. Magnas, Attorney-in-Fact	08/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Protalix (PLX) director Aharon Schwartz report on the Form 4?

The Form 4 reports a purchase of 129,000 shares of Protalix common stock executed on 06/10/2025.

At what price were the PLX shares purchased?

The weighted average purchase price was reported as $1.596 per share, with trade prices ranging from $1.575 to $1.60.

How many PLX shares does the reporting person own after the transaction?

Following the reported purchase, the reporting person beneficially owned 303,000 shares.

What is the reporting person’s relationship to Protalix?

The Form 4 identifies the reporting person, Aharon Schwartz, as a director of Protalix BioTherapeutics.

Was the transaction executed in a single trade or multiple trades?

The filing states the transaction was executed in multiple trades and the weighted average price is reported accordingly.